Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Prospective Multicentre Validation of a Landmark Machine Learning Model for ICU Mortality in Neurocritical Care (LANDMARK-ICU)

11 de noviembre de 2026 actualizado por: Han Chen, Fujian Provincial Hospital

A Prospective Multicentre Observational Study Validating a Landmark-Based Machine Learning Model for Dynamic Prediction of Mortality in Patients Receiving Continuous Intracranial Pressure Monitoring

Mortality prediction in neurocritical care relies on scores computed at admission, which cannot update as the clinical course evolves. We previously developed a landmark-based machine learning model that converts hourly physiological data, including intracranial pressure, into an updating risk of death. The model was developed in a large public database and validated retrospectively in a second, independent one. This prospective multicentre study will test the model in consecutive patients at participating hospitals in Fujian Province, China. Physiological data will be collected as part of routine care. The model will generate risk estimates that are recorded for analysis but not shown to treating clinicians, and no treatment decision will be influenced by the study. The primary analysis will assess discrimination and calibration of the model for death during the intensive care stay. Secondary analyses will compare the model with severity scores in routine use and examine performance by aetiology.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

Model development used the Medical Information Mart for Intensive Care IV database and external validation used the eICU Collaborative Research Database. Both analyses were retrospective and are not part of this registration. This registration covers the prospective multicentre validation only. Inclusion requires age 18 years or older, continuous intracranial pressure monitoring for at least 24 hours, and a diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage. The model uses seven hourly physiological channels with observation masks and elapsed-time features. The primary endpoint is death during the intensive care stay; 28-day mortality, length of stay and Glasgow Outcome Scale at 6 months are secondary. The sample size of 100 patients follows the approved protocol, which assumed area under the curve 0.80 with alpha 0.05 and beta 0.20.

Tipo de estudio

De observación

Inscripción (Estimado)

100

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Fujian
      • Fuzhou, Fujian, Porcelana
        • Fujian Provincial Hospital
      • Fuzhou, Fujian, Porcelana
        • First Affiliated Hospital of Fujian Medical University
      • Quanzhou, Fujian, Porcelana
        • Hui'an County Hospital
      • Quanzhou, Fujian, Porcelana
        • Second Affiliated Hospital of Fujian Medical University
      • Quanzhou, Fujian, Porcelana
        • Shishi City Hospital
      • Zhangzhou, Fujian, Porcelana
        • Zhangzhou Municipal Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 90 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

Adults in intensive care units of participating hospitals who require continuous intracranial pressure monitoring after acute brain injury.

Descripción

Inclusion Criteria:

  • Age 18 years or older
  • Continuous intracranial pressure monitoring for at least 24 hours
  • Diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage
  • Written informed consent from the patient or a legal representative

Exclusion Criteria:

  • Incomplete or unusable intracranial pressure recordings
  • Loss to follow-up or unavailable outcome information
  • Pre-existing severe neurological disease that would confound assessment

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Neurocritical care cohort

Consecutive patients receiving continuous intracranial pressure monitoring, contributing to the risk set at each landmark.

Observational application of a fixed prediction model to hourly physiological data; no treatment is assigned or withheld.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 24-hour landmark
Periodo de tiempo: 24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

Discrimination of the locked landmark model, quantified as the area under the receiver operating characteristic curve, where 0.5 indicates no discrimination and 1.0 perfect discrimination. Death is ascertained from the medical record and the curve is estimated with a 95% confidence interval

24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 48-hour and 72-hour landmarks
Periodo de tiempo: 48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

Same measurement as the primary outcome, estimated separately at the 48-hour and 72-hour landmarks with 95% confidence intervals

48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
Calibration slope (dimensionless) of the landmark model at the 24-, 48- and 72-hour landmarks
Periodo de tiempo: 24, 48 and 72 hours after intensive care admission

Slope obtained by logistic regression of the observed outcome on the logit of the predicted risk; a value of 1 indicates perfect calibration, below 1 indicates over-fitting and above 1 under-fitting.

24, 48 and 72 hours after intensive care admission
Brier score (range 0 to 1) of the landmark model at the 24-, 48- and 72-hour landmarks
Periodo de tiempo: 24, 48 and 72 hours after intensive care admission

Mean squared difference between predicted risk and observed outcome, where lower values indicate better overall performance.

24, 48 and 72 hours after intensive care admission
Difference in area under the receiver operating characteristic curve (range -1 to 1) between the landmark model and the centre-recorded APACHE II score
Periodo de tiempo: 24, 48 and 72 hours after intensive care admission

Paired difference in discrimination, computed as model area under the curve minus APACHE II area under the curve on the same patients, with 95% confidence interval; negative values indicate the model discriminates worse than APACHE II

24, 48 and 72 hours after intensive care admission
Net benefit (dimensionless) of the landmark model from decision-curve analysis at the 24-hour landmark
Periodo de tiempo: 24 hours after intensive care admission

Net benefit computed across threshold probabilities from 0.05 to 0.50, compared with the strategies of treating all patients and treating none

24 hours after intensive care admission
Area under the receiver operating characteristic curve (range 0 to 1) by primary diagnosis at the 24-, 48- and 72-hour landmarks
Periodo de tiempo: 24, 48 and 72 hours after intensive care admission

Discrimination estimated separately for traumatic brain injury, aneurysmal subarachnoid haemorrhage and intracerebral haemorrhage, reported descriptively because stratum sizes are expected to be small

24, 48 and 72 hours after intensive care admission
28-day all-cause mortality, as specified in the approved protocol
Periodo de tiempo: 28 days after intensive care admission
28 days after intensive care admission
Length of intensive care stay
Periodo de tiempo: From intensive care admission to intensive care unit discharge, up to 28 days

Duration of intensive care stay in days, right-censored at day 28 for patients still in intensive care

From intensive care admission to intensive care unit discharge, up to 28 days
Glasgow Outcome Scale score (range 1 to 5, higher is better) at 6 months
Periodo de tiempo: 6 months after intensive care admission

Glasgow Outcome Scale, an ordinal scale from 1 (death) to 5 (good recovery), with higher scores indicating better outcome; assessed by telephone or outpatient follow-up

6 months after intensive care admission

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Han Chen, MD, Fujian Provincial Hospital

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

12 de diciembre de 2027

Finalización del estudio (Estimado)

1 de enero de 2028

Fechas de registro del estudio

Enviado por primera vez

7 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • FJPH-ICP-01

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

De-identified individual participant data will not be shared publicly because small centre volumes could permit re-identification. The model specification, analysis code and summary results will be published.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .